News

Video

Angiogenesis 2024: The implication of longitudinal AI-based fluid quantification for at-home monitoring

Author(s):

Hattie Hayes,Martin David Harp
Conferences|Angiogenesis

Anat Loewenstein, MD, sat down with Hattie Hayes of Ophthalmology Times Europe to discuss the implication of longitudinal AI-based fluid quantification for at-home monitoring from the Angiogenesis Exudation and Degeneration 2024 event.

Anat Loewenstein, MD, sat down with Hattie Hayes of Ophthalmology Times Europe to discuss the implication of longitudinal AI-based fluid quantification for at-home monitoring from the Angiogenesis Exudation and Degeneration 2024 event.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
Related Content
50 years of visionary innovation: Leading ophthalmologists reflect on the field’s greatest breakthroughs
April 18th 2025

50 years of visionary innovation: Leading ophthalmologists reflect on the field’s greatest breakthroughs

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Regeneron’s sBLA for Eylea HD accepted for priority review by FDA
April 17th 2025

Regeneron’s sBLA for Eylea HD accepted for priority review by FDA

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

AI reading label system enhances retinal disease diagnosis and training in ophthalmology
April 13th 2025

AI reading label system enhances retinal disease diagnosis and training in ophthalmology

Vantage Biosciences doses first patient in phase 2 study of VX-01, oral therapy for nonproliferative diabetic retinopathy
April 11th 2025

Vantage Biosciences doses first patient in phase 2 study of VX-01, oral therapy for nonproliferative diabetic retinopathy

© 2025 MJH Life Sciences

All rights reserved.